Finkelstein Thompson LLP Announces Investigation of HealthTronics, Inc.
07 May 2010 - 7:07AM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of HealthTronics, Inc. (“HealthTronics” or
the “Company”) (Nasdaq: HTRN) arising from the Company’s
announcement of its intent to merge with Endo Pharmaceuticals
Holdings Inc. (“Endo Pharmaceuticals”). Under the terms of the
agreement, HealthTronics shareholders will receive $4.85 in cash
for every share of HealthTronics stock they own in a transaction
valued at approximately $223 million plus the assumption of
debt.
The investigation is focused on the potential unfairness of the
consideration to HealthTronics’s shareholders and the process by
which HealthTronics’s Board of Directors considered and approved
the transaction. Indeed, at least one analyst set a price target of
$7.00 per share for HealthTronics stock.
If you are interested in discussing your rights as a
HealthTronics shareholder, or have information relating to this
investigation, please contact Finkelstein Thompson's Washington, DC
offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or co-lead
counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
web site at www.finkelsteinthompson.com. Attorney
advertising. Prior results do not guarantee similar outcomes.
Htetf (MM) (NASDAQ:HTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Htetf (MM) (NASDAQ:HTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Htetf (MM) (NASDAQ): 0 recent articles
More Finkelstein Thompson LLP News Articles